Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1<sup>G93A</sup> amyotrophic lateral sclerosis (ALS) mice

FKBP12 ligands, particularly MP-010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.

Authors

Institutions

Publication Details

Journal
British Journal of Pharmacology
Published
2025-02-13
DOI
https://doi.org/10.1111/bph.17448
Citations
2
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
2.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

José M. Fuentes, Jose Ignacio Miranda, Rosario Osta, Mireia Herrando‐Grabulosa et al.
2 citations
British Journal of Pharmacology
Amyotrophic Lateral Sclerosis Research
2.78
article

Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice

José M. Fuentes, Jose Ignacio Miranda, Rosario Osta, Mireia Herrando‐Grabulosa, Ainara Vallejo‐Illarramendi, Klaudia González-Imaz, Laura Mosqueira‐Martín, Francisco J. Gil‐Bea, Ana Cristina Calvo, J. M. Aizpurua, Núria Gaja‐Capdevila, Laura Moreno‐Martínez, Leticia Moreno‐García, Xavier Navarro, Laura Rodríguez-Gómez, Abraham Acevedo‐Arozena, Maialen Sagartzazu‐Aizpurua, Adolfo López de Munaín
article en
2 citations

Abstract

FKBP12 ligands, particularly MP-010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.

British Journal of PharmacologyVol. 182(11)
Ikerbasque (ES), Universitat Autònoma de Barcelona (ES), University of the Basque Country (ES), Universidad de Zaragoza (ES), Hospital Universitario de Canarias (ES), Biomedical Research Networking Center on Neurodegenerative Diseases (ES), Biogipuzkoa Health Research Institute (ES), Instituto de Investigación Biosanitaria de Granada (ES), Centro de Investigación y Tecnología Agroalimentaria de Aragón (ES), Instituto de Investigación Sanitaria Aragón (ES), Universidad de Extremadura (ES), Universidad de Navarra (ES)
European Commission, Eusko Jaurlaritza, Euskal Herriko Unibertsitatea, Ikerbasque, Basque Foundation for Science, Universidad Pública de Navarra, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación, European Social Fund
Openalex Percentile: Top 12%
Amyotrophic Lateral Sclerosis Research
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.